Literature DB >> 28331420

Serum Procalcitonin in Patients with Acute Liver Failure.

Takaaki Sugihara1, Masahiko Koda1, Toshiaki Okamoto1, Kenichi Miyoshi1, Tomomitsu Matono1, Kenji Oyama1, Keiko Hosho1, Jun-Ichi Okano1, Hajime Isomoto1.   

Abstract

BACKGROUND: Procalcitonin (PCT) is a known diagnostic marker of bacterial infection. There are no previous reports of PCT concerning acute liver failure (ALF). We evaluated the clinical value of serum PCT levels in patients with ALF.
METHODS: Forty-four patients with acute hepatitis (19 men and 25 women; median age, 40 years; range, 20-79 years) were retrospectively enrolled from January 2001 and June 2015. PCT levels were measured by saved serum samples obtained within 3 days after admission. ALF was defined as prothrombin time (PT) < 40% regardless of hepatic encephalopathy.
RESULTS: Serum PCT levels were significantly higher in the patients with ALF (n = 16) than in those with non-ALF (n = 28) [0.25 (0.13-2.66) ng/mL vs. 0.165 (0.03-1.08), P = 0.00967]. Creatinine, total bilirubin, and direct bilirubin were positively correlated, and PT was negatively correlated with PCT. Receiver operating characteristic curve analysis showed an area under the curve of 0.74 for detecting ALF. With a PCT cut-off value of 0.5 ng/mL, the presence of ALF could be demonstrated with low sensitivity (37.5%) and high specificity (96.5%) with high positive (85.7%) and negative (72.9%) predictive value. Multivariate analysis showed that PCT was an independent factor associated with the presence of ALF. The cumulative survival rate was also significantly lower in patients with PCT ≥ 0.5 ng/mL (P = 0.0314), but it was not an independent prognostic factor.
CONCLUSION: Serum PCT level was significantly higher in patients with ALF.

Entities:  

Keywords:  acute hepatitis; acute liver failure; fulminant hepatitis; procalcitonin

Year:  2017        PMID: 28331420      PMCID: PMC5355843     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  32 in total

1.  Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department.

Authors:  Chih-Huang Li; Ruey-Bing Yang; Jong-Hwei S Pang; Shy-Shin Chang; Chih-Chuan Lin; Chien-Hsiun Chen; Hsien-Yi Chen; Te-Fa Chiu
Journal:  Acad Emerg Med       Date:  2011-01-28       Impact factor: 3.451

2.  Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat.

Authors:  D Adawi; F B Kasravi; G Molin; B Jeppsson
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  Pro-inflammatory cytokine release and mediation of the acute phase protein response in fulminant hepatic failure.

Authors:  S J Wigmore; T S Walsh; A Lee; J A Ross
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

Review 4.  Acute liver failure: A curable disease by 2024?

Authors:  William Bernal; William M Lee; Julia Wendon; Fin Stolze Larsen; Roger Williams
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

5.  Prediction of hepatic encephalopathy development in patients with severe acute hepatitis.

Authors:  Yasuhiro Takikawa; Ryujin Endo; Kazuyuki Suzuki; Kenji Fujiwara; Masao Omata
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

6.  Development of an accurate index for predicting outcomes of patients with acute liver failure.

Authors:  Anna Rutherford; Lindsay Y King; Linda S Hynan; Chetan Vedvyas; Wenyu Lin; William M Lee; Raymond T Chung
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

7.  Serum procalcitonin predicts development of acute kidney injury in patients with suspected infection.

Authors:  Xin Nie; Bin Wu; Yong He; Xunbei Huang; Zhongqiu Dai; Qiang Miao; Haolan Song; Tongxing Luo; Baoxiu Gao; Lanlan Wang; Guixing Li
Journal:  Clin Chem Lab Med       Date:  2013-08       Impact factor: 3.694

Review 8.  Acute kidney injury in acute liver failure: a review.

Authors:  Joanna K Moore; Eleanor Love; Darren G Craig; Peter C Hayes; Kenneth J Simpson
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-10-17       Impact factor: 3.869

Review 9.  Acute liver failure in Japan: definition, classification, and prediction of the outcome.

Authors:  Kayoko Sugawara; Nobuaki Nakayama; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2012-07-24       Impact factor: 7.527

Review 10.  Update on procalcitonin measurements.

Authors:  Michael Meisner
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

View more
  6 in total

Review 1.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

2.  Serum procalcitonin and C-reactive protein in the evaluation of bacterial infection in generalized pustular psoriasis.

Authors:  Siyu Wang; Zhen Xie; Zhu Shen
Journal:  An Bras Dermatol       Date:  2019-09-30       Impact factor: 1.896

3.  Procalcitonin in early allograft dysfunction after orthotopic liver transplantation: a retrospective single centre study.

Authors:  Katja Frick; Elisabeth A Beller; Marit Kalisvaart; Philipp Dutkowski; Reto A Schüpbach; Stephanie Klinzing
Journal:  BMC Gastroenterol       Date:  2022-08-31       Impact factor: 2.847

4.  Development of a novel score for the diagnosis of bacterial infection in patients with acute-on-chronic liver failure.

Authors:  Su Lin; Yan-Yan Yan; Yin-Lian Wu; Ming-Fang Wang; Yue-Yong Zhu; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2020-08-28       Impact factor: 5.742

5.  Elevated procalcitonin levels in patients with acetaminophen intoxication: two case reports: A CARE-compliant article.

Authors:  Jung Hwan Ahn; Young Suk Cho; Gyu Chong Cho
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

6.  Extremely Elevated Procalcitonin in a Case of Acetaminophen Overdose and Acute Liver Injury.

Authors:  Yoshito Nishimura; Jakrin Kewcharoen; Toni Narimasu
Journal:  Intern Med       Date:  2021-06-26       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.